Skip to main content

Drug Interactions between fosphenytoin and Tindamax

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fosphenytoin tinidazole

Applies to: fosphenytoin and Tindamax (tinidazole)

MONITOR: Coadministration with a nitroimidazole may increase the serum concentrations of phenytoin. The interaction has been reported with metronidazole, and the proposed mechanism is inhibition of phenytoin metabolism via CYP450 2C9. In one study, metronidazole (250 mg orally three times a day for 4 days) increased the half-life of phenytoin (300 mg single intravenous dose) in healthy volunteers by 44% and reduced its clearance by 15% compared to control values. However, another study found no effect of metronidazole (400 mg orally twice a day) on the pharmacokinetics of orally administered phenytoin (300 mg single dose). No data is available for tinidazole.

MONITOR: Phenytoin may reduce the plasma concentrations of metronidazole and tinidazole by accelerating their metabolism through induction of hepatic microsomal enzymes (e.g., CYP450 3A4).

MANAGEMENT: Pharmacologic response and serum phenytoin levels should be monitored more closely whenever metronidazole is added to or withdrawn from therapy, and the phenytoin (or fosphenytoin) dosage adjusted as necessary. Patients should be advised to notify their doctor if they experience potential symptoms of phenytoin toxicity such as nausea, vomiting, nystagmus, slurred speech, lethargy, tremor, ataxia, hyperreflexia, and dysarthria. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data is lacking. In addition, the potential for reduced efficacy or therapeutic failure of the nitroimidazole should be considered when administered concomitantly with phenytoin or fosphenytoin. Alternative antimicrobial agents or dosage adjustments of the nitroimidazole may be necessary if an interaction is suspected.

References (6)
  1. Jensen JC, Gugler R (1985) "Interaction between metronidazole and drugs eliminated by oxidative metabolism." Clin Pharmacol Ther, 37, p. 407-10
  2. Blyden GT, Scavone JM, Greenblatt DJ (1988) "Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam." J Clin Pharmacol, 28, p. 240-5
  3. (2001) "Product Information. Flagyl (metronidazole)." Searle
  4. (2004) "Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc
  5. (2024) "Product Information. Pylera (bismuth subcitrate potassium/metronidazole/tetracycline)." Flynn Pharma Ltd
  6. (2025) "Product Information. Pylera (bismuth subcitrate potassium/metronidazo/TCN)." H2-Pharma LLC

Drug and food interactions

Moderate

tinidazole food

Applies to: Tindamax (tinidazole)

GENERALLY AVOID: Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients. There have been a few case reports involving metronidazole, although data overall are not convincing. The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram. Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the 'disulfiram reaction'. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmia, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death. However, some investigators have questioned the disulfiram-like properties of metronidazole. One study found neither elevations in blood acetaldehyde nor objective or subjective signs of a disulfiram-like reaction to ethanol in six subjects treated with metronidazole (200 mg three times a day for 5 days) compared to six subjects who received placebo.

MANAGEMENT: Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole. Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.

References (9)
  1. Giannini AJ, DeFrance DT (1983) "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol, 20, p. 509-15
  2. Alexander I (1985) "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract, 39, p. 292-3
  3. Harries DP, Teale KF, Sunderland G (1990) "Metronidazole and alcohol: potential problems." Scott Med J, 35, p. 179-80
  4. Edwards DL, Fink PC, Van Dyke PO (1986) "Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole." Clin Pharm, 5, p. 999-1000
  5. (2002) "Product Information. Flagyl (metronidazole)." Searle
  6. Williams CS, Woodcock KR (2000) "Do ethanol and metronidazole interact to produce a disulfiram-like reaction?." Ann Pharmacother, 34, p. 255-7
  7. Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP (2002) "Lack of disulfiram-like reaction with metronidazole and ethanol." Ann Pharmacother, 36, p. 971-4
  8. Krulewitch CJ (2003) "An unexpected adverse drug effect." J Midwifery Womens Health, 48, p. 67-8
  9. (2004) "Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.